Thomas Karasic, MD

Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced

The efficacy was not particularly notable among the 21 patients on this study, Karasic notes. Five of the patients achieved stable disease for greater than 2 months and 2 of the patients achieved stable disease for greater than 4 months. The patient with the longest duration of response was the only patient who continued trastuzumab (Herceptin) on study.

Videos

Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced&nbsp;<br />
esophageal or gastric cancer.<br />
&nbsp;

Thomas Karasic, MD | Authors

Articles

Results of a Phase II Study of Palbociclib in Esophageal and Gastric Cancer